Riociguat in PAH and CTEPH: Strategies for Patient Management
| العنوان: | Riociguat in PAH and CTEPH: Strategies for Patient Management |
|---|---|
| المؤلفون: | Natalie Kitterman, Traci Stewart, Debra Zupancic, Martha Kingman, Melisa Wilson, Judy Germani |
| المصدر: | Pulmonary Therapy. 3:31-43 |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, medicine.medical_specialty, Elevated pulmonary artery pressure, business.industry, Hemodynamics, 030204 cardiovascular system & hematology, Riociguat, Patient management, Discontinuation, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Respiratory Care, Medicine, 030212 general & internal medicine, business, Intensive care medicine, Adverse effect, medicine.drug, Patient education |
| الوصف: | Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are subtypes of pulmonary hypertension—a rare, life-threatening condition defined by chronically elevated pulmonary artery pressure. Treatment goals include improving patient functioning, symptom management, and delaying disease progression. Traditional therapies have focused on affected physiologic pathways, with endothelin-receptor antagonists and/or phosphodiesterase-5 inhibitors as first-line agents and prostacyclins for more severe disease. Riociguat, a therapeutic agent that stimulates soluble guanylate cyclase via nitric-oxide pathways, was approved in 2013 for treatment of PAH and CTEPH. Riociguat significantly improved exercise capacity, hemodynamic parameters, and other functional endpoints in phase 3 trials. Safety and efficacy were maintained in long-term extension studies. Adverse events (AEs) were generally mild to moderate and self-limiting and did not require treatment discontinuation. To optimize adherence, frequent patient monitoring and management of AEs are recommended. Management strategies include patient education, treatment/prevention of adverse events, and individualized dose adjustment. Funding: Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. |
| تدمد: | 2364-1746 2364-1754 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2326a3eddebe23eeff8d2a37890cab https://doi.org/10.1007/s41030-017-0029-3 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....ca2326a3eddebe23eeff8d2a37890cab |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 23641746 23641754 |
|---|